Evimero LLC
Evimero is an interdisciplinary company focused on understanding the interactions between microorganisms and human health, agriculture, and the environment. Utilizing Systems Biology and AI/ML, Evimero aims to apply microbiome science to improve health outcomes and environmental sustainability through targeted interventions in dysbiotic microbiomes.
Industries
N/A
Nr. of Employees
small (1-50)
Products
A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics
Peer-reviewed article describing a taxonomy-agnostic framework for targeted microbiome therapeutics using systems-biology principles.
Avian antibodies (IgY) targeting SARS-CoV-2 spike glycoprotein
Peer-reviewed study reporting avian IgY targeting SARS-CoV-2 spike protein and its inhibitory effects on receptor binding and viral replication.
Feasibility of avian antibodies as prophylaxis against enterotoxigenic Escherichia coli
Peer-reviewed article assessing avian IgY raised against bacterial adhesion factors as prophylaxis for diarrheal illness caused by ETEC.
Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
Peer-reviewed study exploring the potential of polyclonal avian IgY to prevent human norovirus infection.
A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeutics
Peer-reviewed article describing a taxonomy-agnostic framework for targeted microbiome therapeutics using systems-biology principles.
Avian antibodies (IgY) targeting SARS-CoV-2 spike glycoprotein
Peer-reviewed study reporting avian IgY targeting SARS-CoV-2 spike protein and its inhibitory effects on receptor binding and viral replication.
Feasibility of avian antibodies as prophylaxis against enterotoxigenic Escherichia coli
Peer-reviewed article assessing avian IgY raised against bacterial adhesion factors as prophylaxis for diarrheal illness caused by ETEC.
Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection
Peer-reviewed study exploring the potential of polyclonal avian IgY to prevent human norovirus infection.
Services
End-to-end platform services combining computational causal modeling, laboratory identification, diagnostic assay development, and therapeutic development for microbiome-related problems.
End-to-end platform services combining computational causal modeling, laboratory identification, diagnostic assay development, and therapeutic development for microbiome-related problems.
Expertise Areas
- Microbiome therapeutics and intervention design
- Target discovery and validation in microbial ecosystems
- Computational causal inference and systems-biology modeling
- Diagnostic assay development
Key Technologies
- Causal generative artificial intelligence
- Systems biology modeling
- AI/ML-driven pathway mapping
- Microbiome target discovery
News & Updates
This article discusses insights from the study of human microbiomes and emerging applied therapeutics.
Research on avian antibodies as a response to the COVID-19 pandemic, focusing on their ability to inhibit SARS-CoV-2.
Feasibility of avian antibodies as prophylaxis against enterotoxigenic escherichia coli colonization
This study evaluates the use of avian immunoglobulins as a preventive measure against ETEC-related diarrheal illness.
Research on the potential of avian antibodies to prevent infections caused by human norovirus, a leading cause of viral diarrhea.
This article discusses insights from the study of human microbiomes and emerging applied therapeutics.
Research on avian antibodies as a response to the COVID-19 pandemic, focusing on their ability to inhibit SARS-CoV-2.
Feasibility of avian antibodies as prophylaxis against enterotoxigenic escherichia coli colonization
This study evaluates the use of avian immunoglobulins as a preventive measure against ETEC-related diarrheal illness.
Research on the potential of avian antibodies to prevent infections caused by human norovirus, a leading cause of viral diarrhea.